Teachers Advisors LLC increased its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 1.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 116,924 shares of the company’s stock after buying an additional 1,287 shares during the period. Teachers Advisors LLC owned approximately 0.17% of Myriad Genetics worth $2,245,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of MYGN. Arizona State Retirement System bought a new position in shares of Myriad Genetics during the first quarter valued at about $682,000. Bank of New York Mellon Corp raised its position in shares of Myriad Genetics by 131.2% in the first quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock valued at $17,632,000 after buying an additional 521,146 shares in the last quarter. Frontier Capital Management Co. LLC raised its position in shares of Myriad Genetics by 1.4% in the first quarter. Frontier Capital Management Co. LLC now owns 3,075,954 shares of the company’s stock valued at $59,058,000 after buying an additional 41,432 shares in the last quarter. Great West Life Assurance Co. Can raised its position in shares of Myriad Genetics by 958.4% in the first quarter. Great West Life Assurance Co. Can now owns 97,514 shares of the company’s stock valued at $1,870,000 after buying an additional 88,301 shares in the last quarter. Finally, Bank of Montreal Can raised its position in shares of Myriad Genetics by 5.2% in the first quarter. Bank of Montreal Can now owns 112,150 shares of the company’s stock valued at $2,154,000 after buying an additional 5,529 shares in the last quarter.
Myriad Genetics, Inc. (MYGN) traded up 3.1798% on Friday, reaching $28.7459. 249,335 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $25.39 and its 200 day moving average price is $21.26. The company has a market cap of $1.97 billion, a PE ratio of 90.1125 and a beta of 0.31. Myriad Genetics, Inc. has a 12 month low of $15.15 and a 12 month high of $28.79.
Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.04. The company had revenue of $200.50 million for the quarter, compared to analysts’ expectations of $193.71 million. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. Myriad Genetics’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.36 EPS. On average, equities analysts expect that Myriad Genetics, Inc. will post $1.02 EPS for the current fiscal year.
WARNING: “Myriad Genetics, Inc. (MYGN) Shares Bought by Teachers Advisors LLC” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://transcriptdaily.com/2017/08/18/myriad-genetics-inc-mygn-shares-bought-by-teachers-advisors-llc.html.
Several research analysts recently issued reports on MYGN shares. BidaskClub lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Deutsche Bank AG increased their target price on shares of Myriad Genetics from $15.00 to $20.00 and gave the stock a “sell” rating in a research note on Monday, May 8th. Zacks Investment Research lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. J P Morgan Chase & Co reissued an “underweight” rating and set a $16.00 target price on shares of Myriad Genetics in a research note on Friday, June 30th. Finally, Cowen and Company reissued a “hold” rating and set a $25.00 target price on shares of Myriad Genetics in a research note on Friday, July 14th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $21.22.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.